The other primary indications were critically ill conditions (26 of 903 [2.9%]), increased respiratory support (15 of 903 [1.7%]), apnea (9 of 903 [1.0%]), hypotension (9 of 903 [1.0%]), cardiac arrest (7 of 903 [0.8%]), compensation for blood loss for laboratory or diagnostic tests (based on sample blood volume, irrespective of Hb level) (5 of 903 [0.6%]), patent ductus arteriosus (5 of 903 [0.6%]), inadequate weight gain (1 of 903 [0.1%]), tachypnea (1 of 903 [0.1%]), and ventricular septal defect (1 of 903 [0.1%]). The gene discussed is GSTM1; the disease is Patent ductus arteriosus.